ReviewCureus2026
Nutritional Care for Adults With Obesity Treated With Glucagon-Like Peptide (GLP)-1 and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide‑1 receptor agonists (GLP‑1 RAs) and dual glucose‑dependent insulinotropic polypeptide/glucagon-like peptide‑1 receptor agonists (GIP/GLP‑1 RAs) have rapidly advanced obesity treatment, producing weight‑loss outcomes that exceed previous pharmacologic options. Despite their growing use, nutrition-focused clinical guidance has not kept pace, leaving practitioners responsible for supporting safe therapy implementation with gaps. This review summarizes current evidence on the nutritional implications of GLP‑1-based pharmacotherapy in adults with obesity, including common gastrointestinal adverse events, reduced energy intake, potential macro‑ and micronutrient inadequacies, and risks of lean mass loss. To address these gaps, we introduce an evidence-informed nutrition framework to guide health care professionals in assessment, diagnosis, intervention, and monitoring during GLP‑1 therapy. A structured literature search of peer‑reviewed studies published between 2015 and 2025 was conducted using PubMed, Embase, and Google Scholar. Across randomized controlled trials, GLP‑1 and dual GIP/GLP-1 therapies produced mean weight reductions of approximately 5% to more than 20%, with gastrointestinal symptoms frequently reported and often impacting dietary tolerance. Evidence also suggests early reductions in caloric intake and inadequate consumption of several essential nutrients, while long‑term data on micronutrient status and body composition remain limited. Findings emphasize the need for proactive, individualized medical nutrition therapy to optimize treatment tolerance, preserve lean mass, prevent nutrient deficiencies, and support sustainable outcomes. The proposed nutrition framework offers a structured clinical approach to address these challenges. Future research should focus on longitudinal dietary assessment, biomarker monitoring, and validation of standardized nutrition protocols for patients receiving GLP‑1-based obesity pharmacotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.